[ back to News ]

Concert Pharmaceuticals to Participate on a Private Company Panel at the Merriman Curhan Ford 6th Annual Investor Summit

November 3 , 2009

Lexington, MA -- Concert Pharmaceuticals, Inc. announced today that Roger Tung, Ph.D., President and Chief Executive Officer of Concert, will participate on the Healthcare Private Company Panel at the Merriman Curhan Ford 6th Annual Investor Summit on Tuesday, November 10, 2009 at 2:00 p.m. eastern time.  The one day conference is being held at the Sofitel New York in New York City.

About Concert

Concert Pharmaceuticals is a clinical stage biotechnology company focused on the application of deuterium chemistry to create novel and differentiated small molecule drugs. Concert’s approach leverages known activity and safety of existing drugs to reduce time, risk and expense of drug research and development.  The Company has a broad research pipeline encompassing many therapeutic areas including infectious disease and renal disease, among others.  Its lead development candidate is the HIV protease inhibitor CTP-518.  In 2009, Concert entered into a potential $1 billion collaboration with GlaxoSmithKline to develop and commercialize certain deuterium-containing medicines.  Founded in 2006, Concert has raised more than $110 million of venture and institutional capital.  For more information on Concert Pharmaceuticals, please visit www.concertpharma.com.

Concert Pharmaceuticals and the CoNCERT logo are trademarks of Concert Pharmaceuticals, Inc.

[ back to top ]